Sagus Sampath1, Paul Frankel2, Bianca Del Vecchio3, Nora Ruel2, Bertram Yuh4, An Liu3, Tsung Tsai3, Jeffrey Wong3. 1. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California. Electronic address: ssampath@coh.org. 2. Department of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope National Medical Center, Duarte, California. 3. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California. 4. Department of Urological Surgery, City of Hope National Medical Center, Duarte, California.
Abstract
PURPOSE: The primary objectives of this study were to evaluate toxicity of escalating doses of prostate bed stereotactic body radiation therapy and to provide dose recommendations for a phase 2 study. METHODS AND MATERIALS: Patients with organ-confined, node-negative prostate cancer who had biochemical failure (prostate-specific antigen [PSA] less than 2.0) after prostatectomy were eligible for this phase 1 dose-escalation trial. Doses delivered were 35 Gy, 40 Gy, and 45 Gy in 5 fractions, given every other day. Dose-limiting toxicity (DLT) was defined as Common Terminology Criteria for Adverse Events (version 4.0) grade 3 or higher gastrointestinal or genitourinary (GU) toxicity within 90 days of treatment. Maximum tolerated dose was the highest dose to be tested where fewer than 2 of the patients experienced DLT. Patients completed quality-of-life questionnaires at regular time intervals. RESULTS: Twenty-six patients completed treatment between October 2013 and December 2017. Three patients received 35 Gy, 8 patients received 40 Gy, and 15 patients received 45 Gy. The median follow-up was 60 months for 35 Gy, 48 months for 40 Gy, and 33 months for 45 Gy. No acute DLT events were observed. Late grade ≥2 and ≥3 gastrointestinal toxicity occurred in 11% and 0%, respectively, and late grade ≥2 and ≥3 GU toxicity occurred in 38% and 15%, respectively. No difference was observed in late GU toxicity between 40 Gy and 45 Gy. Sexual function scores were significantly lower in the patients receiving androgen deprivation therapy (P < .01). In all patients, the crude rate of PSA control (<0.2 ng/mL) was 11 out of 26 (42%). CONCLUSIONS: Dose escalation to 45 Gy did not result in acute DLT events, had similar rates of late grade 3 toxicity, and did not demonstrate higher rates of PSA control, compared with 40 Gy. While allowing for higher plan heterogeneity, the recommended dose for phase 2 study will be 40 Gy in 5 fractions.
PURPOSE: The primary objectives of this study were to evaluate toxicity of escalating doses of prostate bed stereotactic body radiation therapy and to provide dose recommendations for a phase 2 study. METHODS AND MATERIALS: Patients with organ-confined, node-negative prostate cancer who had biochemical failure (prostate-specific antigen [PSA] less than 2.0) after prostatectomy were eligible for this phase 1 dose-escalation trial. Doses delivered were 35 Gy, 40 Gy, and 45 Gy in 5 fractions, given every other day. Dose-limiting toxicity (DLT) was defined as Common Terminology Criteria for Adverse Events (version 4.0) grade 3 or higher gastrointestinal or genitourinary (GU) toxicity within 90 days of treatment. Maximum tolerated dose was the highest dose to be tested where fewer than 2 of the patients experienced DLT. Patients completed quality-of-life questionnaires at regular time intervals. RESULTS: Twenty-six patients completed treatment between October 2013 and December 2017. Three patients received 35 Gy, 8 patients received 40 Gy, and 15 patients received 45 Gy. The median follow-up was 60 months for 35 Gy, 48 months for 40 Gy, and 33 months for 45 Gy. No acute DLT events were observed. Late grade ≥2 and ≥3 gastrointestinal toxicity occurred in 11% and 0%, respectively, and late grade ≥2 and ≥3 GU toxicity occurred in 38% and 15%, respectively. No difference was observed in late GU toxicity between 40 Gy and 45 Gy. Sexual function scores were significantly lower in the patients receiving androgen deprivation therapy (P < .01). In all patients, the crude rate of PSA control (<0.2 ng/mL) was 11 out of 26 (42%). CONCLUSIONS: Dose escalation to 45 Gy did not result in acute DLT events, had similar rates of late grade 3 toxicity, and did not demonstrate higher rates of PSA control, compared with 40 Gy. While allowing for higher plan heterogeneity, the recommended dose for phase 2 study will be 40 Gy in 5 fractions.
Authors: Amit Roy; Olga Green; Randall Brenneman; Walter Bosch; Hiram A Gay; Jeff M Michalski; Brian C Baumann Journal: Clin Genitourin Cancer Date: 2022-01-11 Impact factor: 3.121
Authors: Paul H Frankel; Vincent Chung; Joseph Tuscano; Tanya Siddiqi; Sagus Sampath; Jeffrey Longmate; Susan Groshen; Edward M Newman Journal: JAMA Netw Open Date: 2020-05-01
Authors: Christina Schröder; Hongjian Tang; Paul Windisch; Daniel Rudolf Zwahlen; André Buchali; Erwin Vu; Tilman Bostel; Tanja Sprave; Thomas Zilli; Vedang Murthy; Robert Förster Journal: Cancers (Basel) Date: 2022-01-29 Impact factor: 6.639
Authors: Neil R Parikh; Amar U Kishan; Nathanael Kane; Silvia Diaz-Perez; Ekambaram Ganapathy; Ramin Nazarian; Carol Felix; Colleen Mathis; Margaret Bradley; Ankush Sachdeva; Bashir Wyatt; Vince Basehart; Nazy Zomorodian; Lin Lin; Christopher R King; Patrick A Kupelian; Matthew B Rettig; Michael L Steinberg; Minsong Cao; Beatrice S Knudsen; David Elashoff; Dorthe Schaue; Robert E Reiter; Nicholas G Nickols Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-17 Impact factor: 7.038